Herein, imidazole acids grafted chitosan derivatives were synthesized, including HACC, HACC derivatives, TMC, TMC derivatives, amidated chitosan and amidated chitosan bearing imidazolium salts. The prepared chitosan derivatives were characterized by FT-IR and ¹H NMR. The tests evaluated the biological antioxidant, antibacterial, and cytotoxic activities of chitosan derivatives. The antioxidant capacity (DPPH radical, superoxide anion radical and hydroxyl radical) of chitosan derivatives was 2.4–8.3 times higher than that of chitosan. The antibacterial capacity against E. coli and S. aureus of cationic derivatives (HACC derivatives, TMC derivatives, and amidated chitosan bearing imidazolium salts) was more active than only imidazole-chitosan (amidated chitosan). In particular, the inhibition effect of HACC derivatives on E. coli was 15.625 μg/mL. Moreover, the series of chitosan derivatives bearing imidazole acids showed certain activity against MCF-7 and A549 cells. The present results suggest that the chitosan derivatives in this paper seem to be promising carrier materials for use in drug delivery systems.

在此，合成了咪唑酸接枝的壳聚糖衍生物，包括HACC、HACC衍生物、TMC、TMC衍生物、酰胺化壳聚糖和带有咪唑鎓盐的酰胺化壳聚糖。制备的壳聚糖衍生物通过傅立叶变换红外光谱和¹ H NMR 进行了表征。这些测试评估了壳聚糖衍生物的生物抗氧化、抗菌和细胞毒活性。壳聚糖衍生物的抗氧化能力（DPPH自由基、超氧阴离子自由基和羟基自由基）是壳聚糖的2.4-8.3倍。对大肠杆菌和金黄色葡萄球菌的抗菌能力阳离子衍生物（HACC 衍生物、TMC 衍生物和带有咪唑鎓盐的酰胺化壳聚糖）比仅咪唑-壳聚糖（酰胺化壳聚糖）更具活性。特别地，HACC衍生物对大肠杆菌的抑制作用为15.625μg/mL。此外，一系列带有咪唑酸的壳聚糖衍生物对MCF-7和A549细胞显示出一定的活性。目前的结果表明，本文中的壳聚糖衍生物似乎是用于药物输送系统的有前途的载体材料。